e16088 Background: Hispanic patients with gastric adenocarcinoma show distinct clinical patterns, including earlier onset, increased mortality, and a distinct molecular profile. Despite recognition that ethnicity shapes tumor biology and precision oncology access, Latin American real-world data on this disease remain scarce. Methods: We conducted a retrospective observational cohort study of adults diagnosed with gastric adenocarcinoma treated at Fundación Santa Fe de Bogotá between 2010 and 2024. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier (KM) method. Survival curves were compared using the log-rank test, and Cox proportional hazards regression models were performed to identify factors associated with OS and PFS. Results: A total of 166 patients were included; 51.8% were female, with a median age of 66 years (IQR 25). Stage IV disease was frequent (37.6%), predominantly involving the peritoneum (70.4%). Notably, 18.1% of patients were asymptomatic at diagnosis. Diffuse-type histology was most common (47.6%), and 60.6% of tumors were grade III. HER2 overexpression (IHC 3+) and MSI-high status were observed in 6.1% and 6.8%, respectively. Biomarker testing was available in a subset of patients: MSI status was assessed in 79 patients, with 13.9% classified as MSI-high, and HER2 status was evaluated in 106 patients, of whom 13.2% were HER2-positive. Systemic therapy was administered to 82.9% of patients, with chemotherapy as the backbone of treatment (97.0%), the most commonly used regimens were FOLFOX (25.9%) and FLOT (22.3%), followed by CAPEOX (6.0%) and DCF (3.6%). After a median follow-up of 41.0 months using the reverse KM method, median OS and PFS were not reached. Twelve- and 24-month OS rates were 77.6% (95% CI, 70.0–83.6) and 62.9% (95% CI, 54.2–70.4), respectively, while corresponding PFS rates were 58.4% and 41.0%. Disease stage was a strong predictor of both OS and PFS (p < 0.001 for both). OS differed according to MSI status, with MSI-high tumors associated with significantly improved survival (HR 0.13, 95% CI 0.02–0.90; p = 0.048). In contrast, HER2-positive status was not associated with OS (adjusted HR 0.71, 95% CI 0.25–2.00; p = 0.52). Conclusions: Diffuse histology and peritoneal metastasis were frequent in this Hispanic cohort, while HER2 overexpression and MSI-high status were uncommon, limiting targeted and immunotherapy-based approaches. Notably, MSI-high status was associated with significantly improved OS, indicating that the low prevalence of this subtype in our population may contribute to the overall poorer prognostic profile. Despite advanced-stage presentation, survival outcomes were comparable to international real-world series, highlighting the distinct biologic profile of gastric cancer in Hispanic populations and the need for greater representation in clinical research.
Castro et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: